Neuroendocrine TumorVIDEO-NETNCT02147106
Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
An observational study of Neuroendocrine Tumor, run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
Rationale: Patients with neuroendocrine tumors (NET) have a rare disease. Due to treating patients with a neuroendocrine tumor in 'NET knowledge centers' patients often have to travel long distances for follow-up visits at the outpatient clinic. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neuroendocrine Tumor
- What is being tested?
- Videoconsultation
- How many people
- 26 participants
- Where
- 1 siteNetherlands
- Study dates
- May 2014to Mar 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Neuroendocrine tumor patients (grade 1 and 2) whose medical condition allows videoconsultation.
Who may be able to join
- Signed informed consent
- Age ≥ 18 yrs
- Grade I or II (low and intermediate grade) NET with any primary tumor type or disease stage
- Have access to required equipment/technology for performing videoconsultation
Who cannot join
- Newly referred NET patients, who are visiting the department of Medical Oncology at the UMCG for the first time
- Recently diagnosed NET patients, who are in the diagnostic phase of the disease
- NET patients who frequently require blood tests, consultation or physical examination
- A hearing or visual impairment, which would make videoconsultation difficult
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Use of Video Consultation in Follow-up Care for Patients With a NeuroEndocrine Tumor: a Feasibility Study (VIDEO-NET Study)
Rationale: Patients with neuroendocrine tumors (NET) have a rare disease. Due to treating patients with a neuroendocrine tumor in 'NET knowledge centers' patients often have to travel long distances for follow-up visits at the outpatient clinic. Patients whose medical condition allows videoconsultation could save time by replacing outpatient clinic visits through videoconsultation for receiving follow-up care. Therefore, in this study we aim to introduce videoconsultation as a alternative for follow-up outpatient clinic visits in NET patients.
Objective: The primary objective is to assess if use of videoconsultation in follow-up care for NET patients is feasible. We hypothesize that videoconsultation is a suitable medium for providing follow-up care in NET patients. Secondary objectives are to explore the amount of time videoconsultation takes in comparison with outpatient clinic visits and the acceptability and satisfaction of physicians and patients with using videoconsultation in follow-up care.
Read more
Study design: The present study is a single-centre prospective feasibility study.
Study population: Adult NET patients under surveillance or treatment of the department Medical Oncology at the University Medical Centre Groningen (UMCG) whose medical condition allows videoconsultation will be invited to participate.
Intervention: Patient who give informed consent will participate in the study. Participants will receive follow-up care through videoconsultation instead of conventional visits at the outpatient clinic.
Main study parameters/endpoints: The main endpoint is the feasibility of videoconsultation for follow-up care in NET patients. We hypothesize that videoconsultation is a suitable medium for providing follow-up care.
- Conditions
- Neuroendocrine Tumor
- Being tested
- Videoconsultation
- Keywords
- Neuroendocrine tumor, Videoconsultation, Feasibility
- Medical subject headings
- Neuroendocrine Tumors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VideoconsultationOther
| Study group | Role | What they receive |
|---|---|---|
| Videoconsultation | Performing two videoconsulations with the treating medical oncologist Receives: Other: Videoconsultation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility
Participation rates, reason for declining participation, number of completed videoconsultations, dropout rate and reason for dropout will be noted in study records to evaluate feasibility of videoconsultation
Measured: 1 year
Secondary outcomes (3)
Amount of time
The amount of time NET patients are spending with videoconsultation in comparison with conventional outpatient clinic visits.
Measured: 1 year
Acceptability and satisfaction of patients
The acceptability and satisfaction of patients with the use of videoconsultation will be assessed with a questionnaire and open-ended questions.
Measured: 1 year
Acceptability and satisfaction of physicians
The acceptability and satisfaction of physicians with the use of videoconsultation will be assessed with a questionnaire and open-ended questions.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2014 (estimated)
- Study startMay 2014
- Primary completionMar 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuroendocrine TumorStudies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- A.M.E. Walenkamp, MD PhD, Principal investigator, University Medical Center Groningen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02147106
- Sponsor's protocol ID
- VIDEO-NET-2014
- Acronym
- VIDEO-NET
- Status last verified
- May 2024
- First submitted
- 19 May 2014
- Last updated
- 6 May 2024
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of Video Consultation in Follow-up Care for Patients With a NeuroEndocrine Tumor: a Feasibility Study (VIDEO-NET Study)
- ClinicalTrials.gov ID
- NCT02147106
- Acronym / sponsor ID
- VIDEO-NET / VIDEO-NET-2014
- Conditions
- Neuroendocrine Tumor
- Keywords
- Neuroendocrine tumor, Videoconsultation, Feasibility
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- May 2014
- Primary completion
- Mar 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 26 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Patients with neuroendocrine tumors (NET) have a rare disease. Due to treating patients with a neuroendocrine tumor in 'NET knowledge centers' patients often have to travel long distances for follow-up visits at the outpatient clinic. Patients whose medical condition allows videoconsultation could save time by replacing outpatient clinic visits through videoconsultation for receiving follow-up care. Therefore, in this study we aim to introduce videoconsultation as a alternative for follow-up outpatient clinic visits in NET patients.
Objective: The primary objective is to assess if use of videoconsultation in follow-up care for NET patients is feasible. We hypothesize that videoconsultation is a suitable medium for providing follow-up care in NET patients. Secondary objectives are to explore the amount of time videoconsultation takes in comparison with outpatient clinic visits and the acceptability and satisfaction of physicians and patients with using videoconsultation in follow-up care.
Study design: The present study is a single-centre prospective feasibility study.
Study population: Adult NET patients under surveillance or treatment of the department Medical Oncology at the University Medical Centre Groningen (UMCG) whose medical condition allows videoconsultation will be invited to participate.
Intervention: Patient who give informed consent will participate in the study. Participants will receive follow-up care through videoconsultation instead of conventional visits at the outpatient clinic.
Main study parameters/endpoints: The main endpoint is the feasibility of videoconsultation for follow-up care in NET patients. We hypothesize that videoconsultation is a suitable medium for providing follow-up care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Videoconsultation | – | Other: VideoconsultationPerforming two videoconsulations with the treating medical oncologist |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Neuroendocrine tumor patients (grade 1 and 2) whose medical condition allows videoconsultation.
Key inclusion criteria (4 listed)
- Signed informed consent
- Age ≥ 18 yrs
- Grade I or II (low and intermediate grade) NET with any primary tumor type or disease stage
- Have access to required equipment/technology for performing videoconsultation
Key exclusion criteria (4 listed)
- Newly referred NET patients, who are visiting the department of Medical Oncology at the UMCG for the first time
- Recently diagnosed NET patients, who are in the diagnostic phase of the disease
- NET patients who frequently require blood tests, consultation or physical examination
- A hearing or visual impairment, which would make videoconsultation difficult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Videoconsultation | Other | Videoconsultation |
Primary outcome
Feasibility
Time frame: 1 year
Participation rates, reason for declining participation, number of completed videoconsultations, dropout rate and reason for dropout will be noted in study records to evaluate feasibility of videoconsultation
3 secondary outcomes
Amount of time
Time frame: 1 year
Acceptability and satisfaction of patients
Time frame: 1 year
Acceptability and satisfaction of physicians
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2024.
Related trials for Neuroendocrine Tumor
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 2/3
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
A.M.E. Walenkamp, MD PhD principal investigator
University Medical Center Groningen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuroendocrine Tumor, run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2024; AzTrials last refreshed its copy on 8 Nov 2026.